Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Brief Genetics Reports

KIR6.2 Polymorphism Predisposes to Type 2 Diabetes by Inducing Overactivity of Pancreatic β-Cell ATP-Sensitive K+ Channels

  1. Christina Schwanstecher,
  2. Ulrike Meyer and
  3. Mathias Schwanstecher
  1. From the Institute of Pharmacology and Toxicology, University of Braunschweig, Braunschweig, Germany.
    Diabetes 2002 Mar; 51(3): 875-879. https://doi.org/10.2337/diabetes.51.3.875
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Abstract

    E23K, a common single nucleotide polymorphism in KIR6.2, the pore-forming subunit of pancreatic β-cell ATP-sensitive K+ channels, significantly enhanced open probability of these channels, thus reducing their sensitivity toward inhibitory ATP4− and increasing the threshold concentration for insulin release. Previous association studies and high allelic frequency suggest this effect to critically inhibit secretion and play a major role in pathogenesis of common type 2 diabetes. Based on evidence for functional relevance of E23K in both the heterozygous (E/K; with E in position 23 of KIR6.2 in one allele and K in the other) and homozygous (K/K; with K in position 23 of KIR6.2 in both alleles) genotype, we propose a model in which enhanced susceptibility to type 2 diabetes is associated with evolutionary advantage of the E/K state.

    Type 2 diabetes is generally perceived as a polygenic disorder, with disease development being influenced by both hereditary and environmental factors (1). Genes encoding for key components of insulin secretion and glucose metabolism pathways have been widely considered as targets for defects in type 2 diabetes. However, despite intensive investigations, little progress has been made in identifying the genes that impart susceptibility to the common late-onset forms of the disease (2).

    In pancreatic β-cells, ATP-sensitive K+ (KATP) channels critically control insulin secretion by coupling metabolism to electrical activity (3). Recent advances resulted in cloning of these channels and elucidation of their subunit composition (4). The β-cell channels are assembled, with tetradimeric stoichiometry, from two structurally distinct subunits: an inwardly rectifying K+ channel subunit (KIR6.2), forming the pore, and the regulatory sulfonylurea receptor subunit-1 (SUR1). While hypoglycemic sulfonylureas (e.g., glibenclamide) exert their effects on channel activity by interaction with SUR1, there is strong evidence that the receptor site for inhibitory ATP4− is formed by KIR6.2.

    Three common missense single nucleotide polymorphisms (SNPs) have been observed in KIR6.2 (E23K, L270V, and I337V) (5–9), and their potential impact in type 2 diabetes led us to analyze their functional relevance. Whereas L270V and I337V were without effect on the properties of reconstituted human SUR1/KIR6.2 channels (including expression rate, single channel conductance, spontaneous open probability [PO], and nucleotide and drug sensitivities [results not shown]), E23K markedly affected channel gating, significantly reducing the time spent in long interburst closed states (17 ± 3% for SUR1/the mutant isoform of KIR6.2 with K instead of E in position 23 [KIR6.2E23K] vs. 54 ± 6% for wild-type channels, n = 10 each, P < 0.001) (Fig. 1A and B), thus producing a 1.6-fold increase of PO (PO = 0.66 ± 0.05 for SUR1/KIR6.2E23K vs. 0.41 ± 0.04 for wild-type channels, n = 10 each, P < 0.001). The increase of PO was confirmed by noise analysis (patches with 100–500 channels; PO = 0.85 ± 0.04 for SUR1/KIR6.2E23K vs. 0.58 ± 0.03 for wild-type channels, n = 10 each, P < 0.001) and determination of the maximal increment of the spontaneous patch current (ΔImax; PO = 0.77 ± 0.04 for SUR1/KIR6.2E23K vs. 0.52 ± 0.02 for wild-type channels, n = 10 each, P < 0.001) (Fig. 1C). Importantly, a model for the heterozygous genotype (E/K, with E in position 23 of KIR6.2 in one allele and K in the other; coexpression of KIR6.2E23K and the wild-type isoform of KIR6.2 [KIR6.2wt], with a cDNA ratio of 1:1) (Fig. 1C) resulted in intermediate PO values (0.67 ± 0.02 and 0.61 ± 0.02 from noise analysis and measurement of ΔImax, respectively; n = 10; P < 0.01 for comparison with pure wild-type channels each).

    Consistent with the idea that nucleotide-induced channel inhibition results from interaction with the interburst closed states (10,11), E23K decreased sensitivity toward inhibitory ATP4− in the models for the heterozygous (E/K) and homozygous (K/K; with K in position 23 of KIR6.2 in both alleles) genotype by 1.4- and 2.2-fold, respectively (IC50 = 12.4 ± 0.3 μmol/l for coexpression of KIR6.2E23K with KIR6.2wt and 19.7 ± 0.5 μmol/l for pure SUR1/KIR6.2E23K channels vs. 8.9 ± 0.2 μmol/l for pure wild-type channels; n = 15 each; P < 0.01 or <0.001 for comparison with wild-type channels, respectively) (Fig. 2A and B).

    Stimulation of insulin secretion requires reduction of the PO of pancreatic β-cell KATP channels to values <0.02 (12). Both increased spontaneous PO values (Fig. 1), and reduced ATP sensitivity (Fig. 2A) contributed to a rightward shift of the corresponding ATP concentration (ICR2, defined as the ATP concentration that suppresses PO to the threshold for insulin secretion [0.02]) through E23K (Fig. 2B). This shift amounted to 1.5- or 3.1-fold in the models for the E/K and K/K state, respectively (ICR2 = 154 ± 6 μmol/l for coexpression of KIR6.2E23K with KIR6.2wt and 303 ± 11 μmol/l for pure SUR1/KIR6.2E23K channels vs. 98 ± 4 μmol/l for pure wild-type channels, n = 15 and P < 0.001 for comparison with wild-type channels each). The effect of E23K on the ICR2 value was not altered by additional introduction of L270V and/or I337V (Fig. 2C).

    All results obtained with the human isoforms were confirmed in channels reconstituted from mouse KIR6.2 plus hamster SUR1 (results not shown). Effects of E23K on PO and ATP sensitivity were consistent with previous reports on the role of the KIR6.2 NH2 terminus (10,11,13).

    Results indicate that E23K in KIR6.2 significantly affects properties of pancreatic β-cell KATP channels, increasing spontaneous PO and reducing ATP sensitivity in models for the heterozygous (E/K) and homozygous (K/K) state (Figs. 1 and 2). Both effects contribute to a rightward shift of the ATP concentration required to suppress channel activity to the threshold for insulin secretion (ICR2) (Fig. 2B), implying that E23K might induce a critical inhibition of release.

    This idea is strongly supported by recent reports that demonstrate that lowering ATP sensitivity by no more than 3.6-fold induces severe neonatal diabetes in transgenic mice (3), and that reveal clear association of homozygous E23K (K/K) with type 2 diabetes in Caucasians (overall χ2 = 21.3 with 1 df, P < 0.000004) (8,9). Particularly, the latter studies suggest that because of its high allelic prevalence (weighted averaged estimate in Caucasians = 34%) (5–9), E23K is of considerable importance in the pathogenesis of common type 2 diabetes.

    Additional evidence in favor of E23K derives from reinterpretation of published association studies (5–8,14–16), as follows:

    • Partial absence of coupling with E23K led to a lack of detectable association of homozygous I337V with type 2 diabetes (8), arguing against localization of the disease locus downstream (i.e., in the 3′ direction) codon 337 of the KIR6.2 gene.

    • Besides codon 270, there is no additional common missense SNP within the KIR6.2 gene (5–8), excluding KIR6.2 as potential site for an alternative causative variant.

    • At 7.5 kb from the 5′ end of the KIR6.2 gene, a common missense SNP in codon 1369 of the SUR1 gene was found to be in linkage disequilibrium with E23K in KIR6.2 (>77%) (6). In another population, however, linkage could not be confirmed (8,16), and thus, similar to the conclusion drawn above, localization of the causative variant upstream (i.e., in the 5′ direction) codon 1369 in the SUR1 gene seems unlikely.

    • Regions coding for the COOH terminus of SUR1 (exons 33–39) did not enclose any further common SNPs with potential functional relevance (14,16); hence, so far the only alternative candidate chromosomal section left would be that in-between the genes for SUR1 and KIR6.2, encompassing the promoter region of KIR6.2 (17). Modulation of KIR6.2 expression, however, is presumably not involved because isolated targeted overexpression of KIR6.2 does not lead to enhanced formation of functional channels (3).

    We conclude that E23K promotes development of type 2 diabetes by increasing the threshold ATP concentration, thus inducing overactivity of pancreatic β-cell KATP channels and inhibiting insulin secretion. This model is consistent with the postulated critical role of an inborn secretory defect in the genesis of type 2 diabetes (1).

    The conclusion that E23K may induce a discrete inhibition of insulin secretion is supported by a study in healthy young adults (7). Here, E23K was associated with either direct (slightly reduced glucose-stimulated release) or indirect (elevated insulin sensitivity or glucose effectiveness) (examples in 18,19) evidence for decreased secretion. However, because most of these effects did not reach statistical significance, definite proof of reduced secretion will require additional, more detailed clinical studies.

    High allelic frequency of E23K in Caucasians (see above) with similar values in all populations screened (5–9) suggests that E23K represents a balanced polymorphism, conferring selectionary advantage through fine-tuning of insulin secretion in heterozygotes. By reducing glucose uptake in muscle and fat, discrete inhibition of release might result in favorable substrate supply for tissues with insulin-independent uptake, and hence high frequency of the E/K state (∼45%) (5–9) might have evolved as an adaptation to the human brain. Notably, this model implies increased susceptibility to type 2 diabetes as an inherent price for the evolutionary benefit of the heterozygous state, and thus E23K provides evidence in support of the “thrifty genotype” hypothesis (20). However, diverging from this concept, predisposition might have evolved as a response to altered tissue demands rather than periodic famine.

    Early studies (5–7) were unable to reveal the impact of E23K because they were not designed to detect a trait with a relative risk as low as 2, based on small quantitative changes of channel properties. Specifically, the number of probands in initial association studies (5–7) were too low to reach statistical significance, and functional analysis was restricted to assessment of end points of metabolic channel control (5). The latter presumably prompted failure to detect relevance of the polymorphism because E23K affects neither maximal nucleoside diphosphate–induced channel activation (i.e., metabolic inhibition through 3 mmol/l azide [5]) nor maximal ATP-mediated closure (i.e., millimoles per liter of resting ATP levels [5]) (Fig. 1C).

    A recent family-based study failed to replicate association between E23K and type 2 diabetes (21). However, this contradictory result is presumably explained by weak predisposition through the heterozygous state plus specific selection of probands with type 2 diabetes. The study did not focus on the typical type 2 diabetic patient but was mainly grounded on younger probands with prediabetic irregularities of glucose homeostasis. Yet here, discrete inhibition of insulin release is expected to be balanced by compensatory mechanisms (e.g., increased insulin sensitivity or glucose effectiveness; see above).

    The present report is the first to identify the subtle variation of KATP channel function that is induced by E23K in KIR6.2. We infer that this functionally relevant SNP plays an important role in the pathogenesis of common type 2 diabetes and propose a model in which predisposition results as an implicit price for advantage associated with the heterozygous state.

    RESEARCH DESIGN AND METHODS

    Materials.

    All chemicals were obtained from the sources described elsewhere (22).

    Molecular biology.

    Point mutations were introduced into human (GenBank Q14654) or mouse (GenBank D50581) KIR6.2 by standard molecular biology techniques, and constructs were sequenced to verify PCR fidelity before transfection. For analysis of combinations of the polymorphisms (Fig. 2C), mutations were sequentially introduced into the same KIR6.2 cDNA.

    Electrophysiology.

    Transfections were performed as described (22). COS-1 cells were cultured in Dulbecco’s modified Eagle’s medium–high glucose (DMEM-HG) (10 mmol/l glucose) supplemented with 10% FCS, plated at a density of 8 × 104 cells/dish (35 mm), and allowed to attach overnight. For analysis of single-channel kinetics (Fig. 1A and B), 2 μg of pECE-human SUR1 (GenBank NP_000343) complementary DNA and 2 μg of pECE-human KIR6.2 complementary DNA were mixed and used to transfect six 35-mm plates. Amounts of complementary DNA used in transfections for patches with >100 channels (Figs. 1C and 2) were 10-fold higher (20 μg each) than those for measurement of single-channel kinetics. In controls we used pECE-hamster SUR1 (GenBank A56248) and pECE-mouse KIR6.2 instead of the human isoforms. For transfection the cells were incubated for 4 h in a Tris-buffered salt solution containing DNA (5–10 μg/ml) plus DEAE-dextran (1 mg/ml), 2 min in HEPES-buffered salt solution plus DMSO (10%), and 4 h in DMEM-HG plus chloroquine (100 μmol/l). Cells were then returned to DMEM-HG plus 10% FCS. Experiments in the inside-out configuration of the patch-clamp technique were performed 1–2 days after transfection at room temperature. Membrane patches were clamped at −50 mV. The intracellular bath solution contained (in mmol/l): 140 KCl, 2 CaCl2, 10 EDTA, and 5 HEPES (pH 7.15). The pipette solution contained (in mmol/l): 140 KCl, 2.6 CaCl2, 1.2 MgCl2, and 10 HEPES (pH 7.4).

    Open and closed time distributions in single-channel registrations (Fig. 1B) were analyzed using pCLAMP Software version 6.0 (Axon Instruments, Union City, CA). TO is the time constant of the open state; TC1, TC2, A1, and A2 are time constants or relative fractions of short (intraburst) or long (interburst) closed states, respectively. The fraction of time spent in long interburst closed states (PC2) was calculated with PC2 = (TC2 × A2)/(TC1 × A1 + TC2 × A2) × (1 − PO), where PO is the mean PO (in the absence of drugs and nucleotides) calculated from single-channel current registrations (see below).

    For calculation of PO from single-channel currents, only records without superimposed openings were accepted. PO was calculated by dividing the total time the channel spent in the open state by the sample time (30 s). For assessment of PO by noise analysis (10) or determination of the maximal current increment (ΔImax) (Fig. 1C), patches with multiple channels were used. Density of KATP channels per patch ranged from 100 to 500. Estimates of PO were not affected by this variation. In coexpression experiments (KIR6.2wt plus KIR6.2E23K with a cDNA ratio of 1:1) (Fig. 1C), patches with >150 channels were chosen to attain an acceptable frequency of each channel species (22). PO was calculated with PO = 1 − [ς2/(i × I)] or PO = I/(I + ΔImax), respectively, where I is the mean spontaneous patch current (in the absence of drugs and nucleotides), ς2 is the variance, i is the single channel current, and ΔImax is the increment of the patch current induced by the simultaneous addition of 0.3 mmol/l diazoxide plus 3 mmol/l GDP (Fig. 1C).

    For analysis of ATP sensitivity (Fig. 2), patches were chosen with little “run-down” over the measuring period, and effects were corrected for this loss of channel activity by use of linear interpolation. Artifacts caused by incomplete wash-out or slow reversibility were excluded by making sure that experiments with stepwise decrease of the ATP4− concentration yielded EC50 values and slope factors identical to those from experiments with stepwise increases of the concentration. Variation of channel densities (see above) did not affect percentage of sensitive channels, EC50 values, or Hill coefficients (Fig. 2B). Curves shown in Fig. 2B were normalized to PO values calculated from single-channel registrations because we felt these estimates to be more accurate than determinations by noise analysis or measurement of ΔImax (see above). The equivalent value for the 1:1 coexpression, PO-S(1:1), was approximated from the values obtained in patches with multiple channels as follows: PO-S(1:1) = PO-S(wt) + [(PO-S(E23K) − PO-S(wt)) × (PO-M(1:1) − PO-M(wt))/(PO-M(E23K) − PO-M(wt))], where PO-S(wt) and PO-S(E23K) are the PO estimates from single-channel registrations for pure wild-type (0.41) and E23K (0.66) channels, respectively, and PO-M(wt), PO-M(1:1), and PO-M(E23K) are the arithmetic means of corresponding values from noise analysis and determination of ΔImax (0.55, 0.64, and 0.81, respectively; see text).

    Data.

    Data analysis and statistics were performed as described (22). Results are shown as records from representative single experiments (Figs. 1 and 2A) or as the means ± SE (n = 8–16). ICR2 values were estimated by fitting the function PO = 1/[1+([ATP]/IC50)n] to the data of each single experiment, where IC50 is the half-maximally inhibitory ATP-concentration and n is the Hill coefficient. P values were calculated by the Mann-Whitney U test with correction for multiple comparisons or χ2 statistics based on data from Table 2 in ref. 8 and Table 4 in ref. 9.

    FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    E23K induces overactivity of SUR1/KIR6.2 channels by reducing the time spent in interburst closed states. A: Representative single-channel currents recorded from inside-out patches of COS-1 cells transiently coexpressing human SUR1 with wild-type (KIR6.2wt) or mutant KIR6.2 (KIR6.2E23K) (absence of nucleotides). 1 and 0 indicate the open and closed channel levels, respectively. B: Open and closed time distributions from the records shown in part A. Whereas open time distributions did not differ significantly (TO = 3.1 or 3.0 ms for wild-type and mutant channels, respectively), E23K induced a loss of the longer closed events (wild-type channels: TC1 = 0.47 ms, A1 = 83%, TC2 = 45 ms, and A2 = 17%; mutant channels: TC1 = 0.40 ms, A1 = 97%, TC2 = 6.7 ms, and A2 = 3%), where TO is the time constant of the open state; TC1, TC2, A1, and A2 are time constants or relative fractions of short (intraburst) or long (interburst) closed states, respectively. C: E23K reduces the maximal increment of the patch current (ΔImax, see research design and methods). Representative traces recorded from inside-out patches of COS-1 cells transiently coexpressing human SUR1 with KIR6.2wt, KIR6.2E23K, or KIR6.2wt plus KIR6.2E23K (cDNA ratio of 1:1) as indicated. Patches with 100–500 channels were exposed to nucleotides, Mg2+, and diazoxide as shown above the records. Dashed lines indicate spontaneous and maximal channel activity, with maximal activity (PO = 1) being defined by the simultaneous addition of 0.3 mmol/l diazoxide and 3 mmol/l GDP. The distance between these lines corresponds to ΔImax (double-headed arrow). In these single experiments, calculation of spontaneous PO from ΔImax (see research design and methods) gave the following values: 0.47 (wild type), 0.57 (1:1 ratio), and 0.79 (E23K).

    FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    E23K increases the ATP concentration required to suppress PO to 0.02. A: ATP sensitivity of wild-type or mutant SUR1/KIR6.2 channels transiently expressed in COS-1 cells (1:1, cDNA ratio of KIR6.2wt and KIR6.2E23K; see also Fig. 1C). Representative currents were recorded from inside-out patches exposed to ATP4− as shown above the records. Dashed lines indicate residual channel activity (%) in the presence of 10 or 30 μmol/l ATP4−. IC50 values in these registrations were 7.9 μmol/l (wild type), 11.7 μmol/l (1:1 ratio), and 24.6 μmol/l (E23K). B: Concentration-inhibition curves from records as shown in A. Results were normalized to spontaneous PO values determined in single-channel records (KIR6.2wt = 0.41, KIR6.2E23K = 0.66; see text). The equivalent value for the 1:1 coexpression (0.50) was approximated as described under research design and methods. Data are shown as means ± SE (if larger than symbol size) of n = 15 independent experiments. IC50 values for ATP and Hill coefficients were: 8.9 ± 0.2 μmol/l, 1.26 (KIR6.2wt, ○); 12.4 ± 0.3 μmol/l, 1.25 (KIR6.2wt + KIR6.2E23K, cDNA ratio of 1:1, ▪); and 19.7 ± 0.5 μmol/l, 1.28 (KIR6.2E23K, •). The inset shows a magnified view of the y-axis for PO ≤0.04. The horizontal line represents PO = 0.02. Intersections with the concentration-inhibition curves indicate the ATP concentration (ICR2) at which residual activity reaches 2% of maximal channel activity. ICR2 values were 98 ± 4 μmol/l (KIR6.2wt), 154 ± 6 μmol/l (KIR6.2wt + KIR6.2E23K, cDNA ratio of 1:1), and 303 ± 11 μmol/l (KIR6.2E23K). C: The effect of E23K on ICR2 values was not altered by additional introduction of L270V and/or I337V into human KIR6.2. ICR2 values for ATP were calculated based on determination of PO in single-channel registrations (see Fig. 1A) and concentration-inhibition curves as shown in A and B (1:1 coexpression of KIR6.2wt and KIR6.2E23K; see A and B). *P < 0.01 for comparison with the wild type (n = 8–16).

    Acknowledgments

    This work was supported by grants from the Deutsche Forschungsgemeinschaft (to M.S. and C.S.).

    We are grateful to Drs. Lydia Aguilar-Bryan and Joseph Bryan (Baylor College of Medicine, Houston, TX) for providing us with the human isoforms of SUR1 and KIR6.2 and to Drs. Heinz dal Ri (University of Göttingen, Göttingen, Germany) and Colin Nichols (Washington University School of Medicine, St. Louis, MO) for helpful discussion. We thank Haide Fürstenberg, Ursula Herbort-Brand, Claudia Ott, Beate Pieper, Carolin Rattunde, and Petra Weber for their excellent technical assistance.

    Footnotes

    • Address correspondence and reprint requests to Dr. M. Schwanstecher, Institut für Pharmakologie und Toxikologie, Universität Braunschweig, Mendelssohnstraβe 1, 38106 Braunschweig, Germany. E-mail: m.schwanstecher{at}tu-bs.de.

      Received for publication 18 December 2000 and accepted in revised form 29 November 2001.

      DMEM-HG, Dulbecco’s modified Eagle’s medium–high glucose; ICR2, ATP concentration that suppresses spontaneous open probability to the threshold for insulin secretion (0.02); ΔImax, maximal increment of the spontaneous patch current; KATP, ATP-sensitive K+ channel; KIR6.2E23K, mutant isoform of KIR6.2, with K instead of E in position 23; KIR6.2wt, wild-type isoform of KIR6.2; PO, spontaneous open probability; SNP, single nucleotide polymorphism; SUR1, regulatory sulfonylurea receptor subunit-1.

    • DIABETES

    REFERENCES

    1. ↵
      Polonsky KS, Sturis J, Bell GI: Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334: 777–783, 1996
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      Permutt MA, Chiu K, Ferrer J, Glaser B, Inoue H, Nestorowicz A, Stanley CA, Tanizawa Y: Genetics of type II diabetes. Recent Prog Horm Res 53:201–216, 1998
      OpenUrlPubMed
    3. ↵
      Koster JC, Marshall BA, Ensor N, Corbett JA, Nichols CG: Targeted overactivity of β cell KATP channels induces profound neonatal diabetes. Cell 100:645–654, 2000
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Aguilar-Bryan L, Clement JPIV, Gonzalez G, Kunjilwar K, Babenko A, Bryan J: Toward understanding the assembly and structure of KATP channels. Physiol Rev 78:227–245, 1998
      OpenUrlAbstract/FREE Full Text
    5. ↵
      Sakura H, Wat N, Horton V, Millns H, Turner RC, Ashcroft FM: Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in white Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia 39:1233–1236, 1996
      OpenUrlPubMedWeb of Science
    6. ↵
      Inoue H, Ferrer J, Warren-Perry M, Zhang Y, Millns H, Turner RC, Elbein SC, Hampe CL, Suarez BK, Inagaki N, Seino S, Permutt MA: Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. Diabetes 46:502–507, 1997
      OpenUrlAbstract/FREE Full Text
    7. ↵
      Hansen L, Echwald SM, Hansen T, Urhammer SA, Clausen JO, Pedersen O: Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes 46:508–512, 1997
      OpenUrlAbstract/FREE Full Text
    8. ↵
      Hani EH, Boutin P, Durand E, Inoue H, Permutt MA, Velho G, Froguel P: Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of type II diabetes mellitus in Caucasians. Diabetologia 41:1511–1515, 1998
      OpenUrlCrossRefPubMedWeb of Science
    9. ↵
      Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC: UK Prospective Diabetes Study (UKPDS 53): association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with type 2 diabetes mellitus (UKPDS 53). Diabet Med 18:206–212, 2001
      OpenUrlCrossRefPubMedWeb of Science
    10. ↵
      Koster JC, Sha Q, Shyng S-L, Nichols CG: ATP inhibition of KATP channels: control of nucleotide sensitivity by the N-terminal domain of the Kir6.2 subunit. J Physiol 515:19–30, 1999
      OpenUrlCrossRefPubMedWeb of Science
    11. ↵
      Babenko AP, Gonzalez G, Bryan J: The N-terminus of KIR6: 2 limits spontaneous bursting and modulates the ATP-inhibition of KATP channels. Biochem Biophys Res Commun 255:231–238, 1999
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      Schwanstecher C, Dickel C, Ebers I, Lins S, Zünkler BJ, Panten U: Diazoxide-sensitivity of the adenosine 5′-triphosphate-dependent K+ channel in mouse pancreatic beta-cells. Br J Pharmacol 107:87–94, 1992
      OpenUrlCrossRefPubMed
    13. ↵
      Tucker SJ, Gribble FM, Proks P, Trapp S, Ryder TJ, Haug T, Reimann F, Ashcroft FM: Molecular determinants of KATP channel inhibition by ATP. EMBO J 17:3290–3296, 1998
      OpenUrlAbstract
    14. ↵
      Inoue H, Ferrer J, Welling CM, Elbein SC, Hoffman M, Mayorga R, Warren-Perry M, Zhang Y, Millns H, Turner R, Province M, Bryan J, Permutt MA, Aguilar-Bryan L: Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes 45:825–831, 1996
      OpenUrlAbstract/FREE Full Text
    15. Hani EH, Clement K, Velho G, Vionnet N, Hager J, Philippi A, Dina C, Inoue H, Permutt MA, Basdevant A, North M, Demenais F, Guy-Grand B, Froguel P: Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes 46:688–694, 1997
      OpenUrlAbstract/FREE Full Text
    16. ↵
      Hansen T, Echwald SM, Hansen L, Moller AM, Almind K, Clausen JO, Urhammer SA, Inoue H, Ferrer J, Bryan J, Aguilar-Bryan L, Permutt MA, Pedersen O: Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 47:598–605, 1998
      OpenUrlAbstract
    17. ↵
      Ashfield R, Ashcroft SJ: Cloning of the promoters for the beta-cell ATP-sensitive K-channel subunits Kir6.2 and SUR1. Diabetes 47:1274–1280, 1998
      OpenUrlAbstract/FREE Full Text
    18. ↵
      Tripathy D, Carlsson AL, Lehto M, Isomaa B, Tuomi T, Groop L: Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state. Diabetologia 43:1476–1483, 2000
      OpenUrlCrossRefPubMedWeb of Science
    19. ↵
      Henriksen JE, Levin K, Thye-Ronn P, Alford F, Hother-Nielsen O, Holst JJ, Beck-Nielsen H: Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients. Diabetes 49:1209–1218, 2000
      OpenUrlAbstract
    20. ↵
      Neel JV: The “thrifty genotype” in 1998 (Review). Nutr Rev 57:S2–S9, 1999
      OpenUrlPubMedWeb of Science
    21. ↵
      Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80, 2000
      OpenUrlCrossRefPubMedWeb of Science
    22. ↵
      Markworth E, Schwanstecher C, Schwanstecher M: ATP4− mediates closure of pancreatic beta-cell ATP-sensitive potassium channels by interaction with 1 of 4 identical sites. Diabetes 49:1413–1418, 2000
      OpenUrlAbstract
    PreviousNext
    Back to top

    In this Issue

    March 2002, 51(3)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    KIR6.2 Polymorphism Predisposes to Type 2 Diabetes by Inducing Overactivity of Pancreatic β-Cell ATP-Sensitive K+ Channels
    (Your Name) has forwarded a page to you from Diabetes
    (Your Name) thought you would like to see this page from the Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    KIR6.2 Polymorphism Predisposes to Type 2 Diabetes by Inducing Overactivity of Pancreatic β-Cell ATP-Sensitive K+ Channels
    Christina Schwanstecher, Ulrike Meyer, Mathias Schwanstecher
    Diabetes Mar 2002, 51 (3) 875-879; DOI: 10.2337/diabetes.51.3.875

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    KIR6.2 Polymorphism Predisposes to Type 2 Diabetes by Inducing Overactivity of Pancreatic β-Cell ATP-Sensitive K+ Channels
    Christina Schwanstecher, Ulrike Meyer, Mathias Schwanstecher
    Diabetes Mar 2002, 51 (3) 875-879; DOI: 10.2337/diabetes.51.3.875
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • Acknowledgments
      • Footnotes
      • REFERENCES
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • The Krüppel-Like Factor 11 (KLF11) Q62R Polymorphism Is Not Associated With Type 2 Diabetes in 8,676 People
    • CHRM3 Gene Variation Is Associated With Decreased Acute Insulin Secretion and Increased Risk for Early-Onset Type 2 Diabetes in Pima Indians
    • Polymorphism in the Transcription Factor 7-Like 2 (TCF7L2) Gene Is Associated With Reduced Insulin Secretion in Nondiabetic Women
    Show more Brief Genetics Reports

    Similar Articles

    Navigate

    • Current Issue
    • Online Ahead of Print
    • Scientific Sessions Abstracts
    • Collections
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.